Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 24, 2011. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,170,000 Ordinary shares of 25 pence each.
- Purchase Date: November 24, 2011.
- Price Range: Highest price paid was 1,346.5 pence per share; lowest price paid was 1,321 pence per share.
- Treasury Holdings (Settled): 523,662,927 shares (9.40% of total issued share capital).
- Treasury Holdings (Including Unsettled): 527,332,927 shares (10.44% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,049,401,472 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the acquisition of 1,170,000 shares for Treasury. This action increased the proportion of shares held in Treasury to 9.40% of issued capital and 10.44% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (523,662,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (5,049,401,472 shares in issue) for disclosure threshold assessments.
- Review the price paid per share (1,321 to 1,346.5 pence) to assess the cost of capital return relative to market prices on November 24, 2011.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.